Arrowhead reports FY2026 results, highlights REDEMPLO growth and sNDA submission
Arrowhead posted fiscal 2026 results on Nov. 12, 2026, detailing REDEMPLO prescription growth, an sNDA submission for plozasiran in severe hypertriglyceridemia, and new RNAi pipeline data.
Arrowhead Pharmaceuticals announced financial results for its 2026 fiscal year ended September 30, 2026, on November 12, 2026.1
On the commercial side, the company said REDEMPLO launch in familial chylomicronemia syndrome continued to build momentum, with new to brand prescriptions growing 63% quarter over quarter and cumulative new to brand prescriptions reaching 950 by the end of the quarter, plus 300 more since.1 Weekly prescriptions reached about 50-60, more than 640 unique practitioners had prescribed the drug by quarter end (growing to over 860 since), and 160 million U.S. lives are now covered in payer formulary.1
Internationally, REDEMPLO became available in Germany following European Commission marketing authorization in June 20261, and the UK's MHRA granted marketing authorization, followed by NICE guidance recommending NHS funding for genetically confirmed FCS patients.1
On regulatory strategy, the FDA granted plozasiran entry into its STAR pilot program tied to the company's sNDA for severe hypertriglyceridemia, which Arrowhead submitted while preparing for a potential U.S. launch in the second quarter of 2027.1 Entry into STAR qualifies the application for 6-month Priority Review instead of 10 months, and the company retains a previously purchased Priority Review Voucher since STAR entry makes PRV use unnecessary.1
On pipeline data, SHASTA-3 and SHASTA-4 Phase 3 studies met primary and secondary endpoints, with median triglyceride reductions of 79% and 81%.1 Interim Phase 1/2a data for ARO-DIMER-PA showed the TRiM platform can silence two genes simultaneously in one molecule.1 The company also completed enrollment in the Phase 3 YOSEMITE trial of zodasiran for homozygous familial hypercholesterolemia, expanding target enrollment from 60 to 70 patients.1
On financing, Arrowhead refinanced its Sixth Street credit facility into a new $400 million term loan at SOFR plus 5.50%, down from 15%.1 The board also approved changing the fiscal year end from September 30 to December 31, effective January 1, 2027.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.